



P R E S S R E L E A S E

Three projects, accredited by Lyonbiopole, obtain public funding from the 18th Call for Projects of the Single Inter-Ministry Fund (FUI)

Lyon/Grenoble, on September 30, 2014 – After their accreditation by Lyonbiopole, worldwide competitiveness cluster, the new projects GLIOMTRACKER, PHOSA and SMARTBANDAGE have been selected by the FUI. Since 2005, Lyonbiopole has accredited 165 multi-partner R&D projects for a total R&D investment of € 733 million of which € 300 million have been obtained.

3 new R&D projects, accredited by Lyonbiopole and submitted to the 18th FUI Call for Projects, benefit from public funding from the French State, local authorities among which the Rhône-Alpes Region, the Greater Lyon, General Council of Isère and FEDER European funds.

GLIOMTRACKER (AAP18 FUI)

Tumor surgery guided by fluorescence imaging for glioma cancer

Partners: Fluoptics (project leader), ERAS Labo, CHU de Grenoble – Clinatoc, CEA Leti

This project aims to validate a local partnership through the development and production of innovative fluorescent probe Angiostamp™ for cancer surgery. This probe allows the surgeon to visualize intraoperatively and in real time tumor zones invisible to the naked eye. This project will enable to define the methodology and the bonds between companies, leading to a faster development and a lower price for these new molecules. The target market is the international market of hospitals and clinics.

PHOSA (AAP18 FUI)

Bacteriophages strategy against bone and joint infections caused by *Staphylococcus aureus* and *epidermidis*

Partners: Pherecydes (project leader), Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, Centre International de Recherche en Infectiologie (CIRI), Biofilm Control and Vivexia

Bone and joint infection (BJI) are serious diseases that can be responsible of very severe disability or even be life-threatening. While BJI are usually treated with antibiotics, resistant strains of bacteria are increasing constantly. PHOSA aims at developing a cocktail of lytic bacteriophages effective against BJI caused by *Staphylococcus aureus* and *epidermidis*, particularly against antibiotic multi-resistant strains and infections in the presence of bacterial biofilms.

LYONBIOPOLE

PRESS RELEASE

SMARTBANDAGE (AAP18 FUI)

Microbial biosensor embedded in a bandage

Partners: bioMérieux (project leader), Bluestar Silicones, Fibroline, Montdor, Hospices Civils de Lyon and International Research Center for Infectious Diseases (CIRI)

The number of nosocomial infections and antibiotic resistant bacteria are constantly rising. This critical situation requires to significantly improve early detection and microbiological diagnosis of these infections. Medical reports show that 2% of these infections are caused by skin lesions. The major objective of SMARTBANDAGE is to design a bandage in which wound infection by bacteria associated with nosocomial infections would be rapidly detected.

An update on projects accredited by Lyonbiopole and funded

Since 2005, Lyonbiopole has accredited **165** R&D projects, representing a total investment around of € **733** million and have obtained € **300** million of public funding.

→ FUI calls for projects

45 projects of a total € **212** million investment received public funding totaling € **84** million.

→ ANR calls for projects

106 projects, corresponding to € **170** million of investments and that have obtained € **60** million in funding from the National Research Agency (ANR).

→ ISI Bpifrance and PSPC

6 projects accredited by Lyonbiopole, representing an investment totaling € **331** million, obtained a total € **142** million public funding.

→ Other projects

7 projects accredited by Lyonbiopole and of a total € **22** million investments, obtained a total of € **13** million in funding from the European Commission, Bpifrance and local authorities (except FUI projects).

LYONBIOPOLE

PRESS RELEASE

About Lyonbiopole

As a biocluster, Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in 4 main strategic areas: human medicine, veterinary medicine, in vitro diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields like cancer, nutrition, metabolic diseases and neurosciences. In 2013, Lyonbiopole represented a community of 139 members: 4 world-class leaders as Lyonbiopole's founders (Sanofi Pasteur, bioMérieux, Merial, BD) – 19 Research Centers including 3 Hospital University Centers and almost 116 SMBs.

More information: www.lyonbiopole.com

Press Contacts

Florence Portejoie - +33 (0)1 58 18 32 58 / 06 88 84 81 74 - fportejoie@hbcomcorp.fr
Stéphanie Pelège - +33 (0)4 72 76 53 41 - info@lyonbiopole.com